BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20193963)

  • 1. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
    Muranyi AL; Dedhar S; Hogge DE
    Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
    Arseni N; Ahmed F; Hiddemann W; Buske C; Feuring-Buske M
    Haematologica; 2005 Nov; 90(11):1577-8. PubMed ID: 16266907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
    Griessinger E; Imbert V; Lagadec P; Gonthier N; Dubreuil P; Romanelli A; Dreano M; Peyron JF
    Leukemia; 2007 May; 21(5):877-85. PubMed ID: 17330097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
    Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
    Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
    Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
    Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors.
    Xing Y; Gerhard B; Hogge DE
    Exp Hematol; 2012 Nov; 40(11):922-33. PubMed ID: 22828407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
    Kasper S; Breitenbuecher F; Hoehn Y; Heidel F; Lipka DB; Markova B; Huber C; Kindler T; Fischer T
    Leuk Res; 2008 Nov; 32(11):1698-708. PubMed ID: 18556063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
    Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
    Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
    Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
    Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
    Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
    Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
    Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
    Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.